{
  "schemaVersion": 2,
  "eyebrow": "Rheumatology",
  "title": "Mixed Connective Tissue Disease",
  "summary": "Mixed connective tissue disease requires anti-U1-RNP positivity plus an evolving overlap phenotype. Initial management hinges on detecting pulmonary arterial hypertension, interstitial lung disease, inflammatory myopathy, and cardiac involvement before assigning organ-directed immunosuppression and cardiopulmonary care.",
  "seoDescription": "Physician guide to diagnosing mixed connective tissue disease, defining overlap phenotypes, and screening for pulmonary hypertension, ILD, myositis, and cardiac disease.",
  "clinicalQuestion": "How should clinicians confirm suspected mixed connective tissue disease and prioritize screening for organ-threatening complications?",
  "specialty": "Rheumatology",
  "audience": "U.S. physicians and medical trainees",
  "tags": [
    "mixed connective tissue disease",
    "MCTD",
    "anti-U1-RNP",
    "Raynaud phenomenon",
    "connective tissue disease-associated ILD",
    "pulmonary arterial hypertension",
    "overlap myositis"
  ],
  "keyTakeaways": [
    "Do not diagnose MCTD from anti-U1-RNP alone: establish a compatible evolving overlap phenotype, particularly Raynaud phenomenon, puffy hands, inflammatory arthritis, myositis, sclerodactyly, serositis, ILD, or pulmonary hypertension. [18][19][22]",
    "At meaningful clinical suspicion, obtain nailfold videocapillaroscopy, pulmonary function tests, transthoracic echocardiography, and high-resolution chest CT to identify vascular and pulmonary disease. [19]",
    "Anti-U1-RNP positivity is associated with increased CTD-associated PAH risk (odds ratio 5.30); unexplained dyspnea, declining DLCO, desaturation, or abnormal echocardiography should prompt a pulmonary hypertension-focused evaluation. [16][18]",
    "Treat organ-threatening pulmonary disease as CTD-ILD or CTD-associated PAH rather than as a nonspecific MCTD manifestation; mycophenolate mofetil and cyclophosphamide are described anti-inflammatory options for CTD-ILD, with rituximab considered for rapidly progressive or resistant disease. [5]",
    "Baseline lung involvement predicts incident cardiac involvement in anti-Ku-positive systemic autoimmune disease; in MCTD-spectrum overlap disease, pulmonary symptoms or ILD should heighten surveillance for myocarditis, pericarditis, and pulmonary hypertension. [2]"
  ],
  "sections": [
    {
      "id": "diagnostic-frame",
      "eyebrow": "Diagnosis",
      "heading": "Confirm an MCTD phenotype rather than labeling isolated anti-U1-RNP positivity",
      "intro": "Use phenotype, serology, and organ mapping together because clinical features may emerge sequentially.",
      "paragraphs": [
        "Suspect MCTD when high-titer anti-U1 small nuclear RNP antibodies coexist with an overlap phenotype spanning systemic lupus erythematosus, systemic sclerosis, rheumatoid arthritis-like inflammatory arthritis, and inflammatory myopathy. Raynaud phenomenon, puffy hands, sclerodactyly, synovitis, myositis, serositis, ILD, pulmonary hypertension, and esophageal dysmotility are the most decision-relevant manifestations because they direct vascular, pulmonary, muscle, cardiac, or gastrointestinal evaluation. [18][22]",
        "Anti-U1-RNP is indispensable to the diagnostic construct but is not uniquely specific to MCTD; U1-snRNP antibodies occur in SLE, systemic sclerosis, myositis, and MCTD. Classify the patient by the dominant current organ phenotype while following longitudinally for evolution into a more defined connective-tissue disease or persistent overlap syndrome. [20][24]",
        "The initial laboratory assessment should include complete blood count, complement assessment, muscle enzymes, and serum protein electrophoresis as supportive measures of cytopenia, hypocomplementemia, myositis, or hypergammaglobulinemia. Use these findings to define active organ involvement rather than as stand-alone diagnostic criteria. [19]"
      ],
      "bullets": [
        "Inflammatory arthritis or synovitis with anti-U1-RNP should trigger assessment for erosive disease; joint involvement in MCTD can be erosive. [18]",
        "Proximal weakness, myalgia, dysphagia, or elevated muscle enzymes should trigger a formal inflammatory-myopathy evaluation; myositis may develop later and is rarely the presenting feature. [4][19]",
        "Raynaud phenomenon with puffy hands or sclerodactyly increases concern for a scleroderma-spectrum vascular phenotype and supports nailfold microvascular assessment. [18][19]"
      ],
      "subsections": [],
      "table": {
        "caption": "Clinical patterns that should shift the next diagnostic step in suspected MCTD. [18][19][22]",
        "columns": [
          "Dominant presentation",
          "Most useful next assessment",
          "Interpretation and next action"
        ],
        "rows": [
          [
            "Raynaud phenomenon, puffy hands, sclerodactyly",
            "Nailfold videocapillaroscopy",
            "Microvascular assessment supports a vasculopathic overlap phenotype; pair with cardiopulmonary screening because nailfold abnormalities have been associated with PAH prevalence in MCTD. [19][24]"
          ],
          [
            "Inflammatory arthritis or synovitis",
            "Joint examination plus assessment for structural damage",
            "An RA-like pattern is common; recognize that erosive joint disease can occur and reassess the dominant overlap diagnosis over time. [18][19]"
          ],
          [
            "Weakness, myalgia, dysphagia, elevated muscle enzymes",
            "Muscle enzyme testing and inflammatory-myopathy assessment",
            "Myositis is an important MCTD feature but often develops after initial presentation; evaluate extramuscular disease concurrently. [4][19]"
          ],
          [
            "Dyspnea, reduced exercise tolerance, cough, hypoxemia",
            "PFTs, transthoracic echocardiography, and HRCT",
            "Separate ILD, PAH, and combined cardiopulmonary disease before selecting immunosuppressive or PAH-directed treatment. [18][19]"
          ],
          [
            "Pleuritic pain, pericarditic symptoms, chest pain, cardiac symptoms",
            "Cardiac evaluation with echocardiography; use cardiac MRI when myocarditis is suspected",
            "Pericarditis, myocarditis, and pulmonary hypertension occur across systemic autoimmune overlap phenotypes and require phenotype-specific management. [1][2]"
          ]
        ]
      }
    },
    {
      "id": "baseline-organ-screening",
      "eyebrow": "Organ staging",
      "heading": "Screen early for ILD and pulmonary hypertension",
      "intro": "Pulmonary disease is a leading source of morbidity and mortality in MCTD-spectrum illness.",
      "paragraphs": [
        "Obtain PFTs, transthoracic echocardiography, and HRCT in patients with significant suspicion of MCTD, including those without prominent respiratory symptoms. This approach is intended to identify ILD, pulmonary vascular disease, and early physiologic impairment before severe exertional limitation develops. [19]",
        "For possible PAH, integrate symptoms with DLCO, exercise oxygenation, echocardiography, BNP, and CT features rather than interpreting any isolated screening result. Findings that increase concern include DLCO below 30% predicted or a worsening DLCO with preserved lung volumes, marked or worsening desaturation on 6-minute walk testing, elevated BNP, estimated right ventricular systolic pressure above 45, right ventricular dilation, pulmonary artery-to-aorta ratio above 0.9, or right ventricle-to-left ventricle ratio above 1 on CT. [18]",
        "Confirm PAH hemodynamically when pulmonary hypertension is suspected: the contemporary definition requires mean pulmonary arterial pressure above 20 mmHg at rest, pulmonary artery wedge pressure 15 mmHg or less, and pulmonary vascular resistance greater than 2 Wood units. Distinguish pulmonary arterial disease from pulmonary hypertension attributable to ILD, left-heart disease, thromboembolic disease, or mixed mechanisms before initiating disease-specific treatment. [16][18]",
        "Anti-U1-RNP positivity is associated with greater CTD-associated PAH risk (odds ratio 5.30, 95% CI 2.96-9.48). This association supports a low threshold for repeated cardiopulmonary evaluation when dyspnea, falling DLCO, desaturation, or right-heart abnormalities emerge. [16]"
      ],
      "bullets": [
        "Order HRCT when PFT abnormalities, respiratory symptoms, oxygen desaturation, or suspected ILD are present; NSIP is a reported ILD pattern in connective-tissue disease-associated pulmonary disease. [6][23]",
        "Do not attribute dyspnea to deconditioning until ILD, PAH, myocarditis, pericardial disease, and volume overload have been assessed in the relevant phenotype. [1][2][18]",
        "In anti-U1-RNP-positive CTD-associated PAH, anti-U1-RNP positivity has been associated with lower mortality after PAH develops (hazard ratio 0.55, 95% CI 0.36-0.83), but this does not remove the need for systematic screening. [16]"
      ],
      "subsections": [],
      "table": {
        "caption": "Pulmonary hypertension screening findings that should accelerate diagnostic evaluation. [18]",
        "columns": [
          "Domain",
          "Concerning finding",
          "Clinical implication"
        ],
        "rows": [
          [
            "Pulmonary function",
            "DLCO <30% predicted or worsening DLCO with preserved lung volumes",
            "Raises concern for pulmonary vascular disease; integrate with echocardiography, exercise testing, and thoracic imaging. [18]"
          ],
          [
            "6-minute walk test",
            "Marked/worsening desaturation, declining distance, or heart-rate recovery <13",
            "Supports clinically significant cardiopulmonary limitation and should prompt reassessment for PAH and ILD progression. [18]"
          ],
          [
            "Echocardiography",
            "RVSP >45, RV dilation, reduced TAPSE, or reduced RV fractional area change",
            "Suggests right-ventricular pressure overload or dysfunction; pursue hemodynamic clarification when clinical suspicion is present. [18]"
          ],
          [
            "CT chest",
            "PA:A ratio >0.9 or RV:LV ratio >1",
            "Supports pulmonary hypertension concern while concurrently defining ILD extent and pattern. [18]"
          ],
          [
            "Biomarker",
            "Elevated BNP",
            "Supports possible right-heart strain and should be interpreted with imaging and hemodynamics. [18]"
          ]
        ]
      }
    },
    {
      "id": "organ-directed-management",
      "eyebrow": "Treatment",
      "heading": "Treat the dominant organ-threatening phenotype",
      "intro": "Management is phenotype-directed because MCTD can combine inflammatory, fibrosing, vascular, and cardiac processes.",
      "paragraphs": [
        "For CTD-ILD with an inflammatory phenotype, mycophenolate mofetil or cyclophosphamide are described cornerstone anti-inflammatory therapies; rituximab can be considered when disease is rapidly progressive or resistant. Select treatment after HRCT, PFT, oxygenation, and clinical trajectory establish that ILD is active and clinically consequential rather than incidental stable abnormality. [5]",
        "For pulmonary hypertension, determine whether the physiology is pulmonary arterial disease, ILD-associated pulmonary hypertension, or mixed disease. A reported antisynthetase-overlap case with group 1 and group 3 mechanisms used tadalafil with oxygen support and mycophenolate mofetil for the inflammatory lung disease, illustrating why therapy must address both pulmonary vascular and parenchymal contributors when present. [6]",
        "Inflammatory myopathy should be managed as a myositis phenotype with objective tracking of weakness, dysphagia, and muscle enzyme activity; do not assume that a normal initial muscle assessment excludes future myositis because it is frequently a later manifestation. [4][19]",
        "Pericarditis and suspected myocarditis require cardiac phenotyping rather than empiric escalation for nonspecific chest symptoms. Cardiac MRI was used to define myocarditis in a systemic autoimmune anti-Ku cohort, where myocarditis, pulmonary hypertension, and pericarditis segregated into different clinical clusters. [1][2]"
      ],
      "bullets": [
        "Escalate urgently for resting hypoxemia, rapidly worsening dyspnea, right-heart failure features, new exertional syncope, suspected myocarditis, or rapidly progressive weakness with dysphagia; these presentations require expedited cardiopulmonary or neuromuscular evaluation. [2][6][18]",
        "Use supplemental oxygen when hypoxemic while defining the relative contributions of ILD and pulmonary hypertension; oxygen was required in reported CTD-associated chronic hypoxic respiratory failure with pulmonary hypertension. [6]",
        "Reassess treatment response with the same organ-specific measures that defined disease: symptoms and oxygenation for pulmonary disease, serial PFTs and imaging for ILD, and echocardiographic/hemodynamic assessment for suspected pulmonary vascular progression. [18][19]"
      ],
      "subsections": [
        {
          "heading": "Pulmonary disease treatment decisions",
          "paragraphs": [
            "Do not extrapolate ILD immunosuppression to idiopathic pulmonary fibrosis: immunomodulation may worsen outcomes in IPF, whereas CTD-associated ILD has evidence supporting anti-inflammatory treatment in selected disease. Establish the clinical-radiologic context before treating progressive fibrotic lung disease as inflammatory CTD-ILD. [23]"
          ],
          "bullets": [
            "Consider rituximab when CTD-ILD is rapidly progressive or resistant after assessment of inflammatory versus fibrotic behavior. [5]",
            "When pulmonary hypertension coexists with ILD, assess for multifactorial disease rather than assigning a single pulmonary hypertension mechanism. [6]"
          ]
        }
      ],
      "table": null
    },
    {
      "id": "longitudinal-surveillance",
      "eyebrow": "Follow-up",
      "heading": "Use phenotype evolution to drive surveillance",
      "intro": "The diagnostic label may remain stable while the dominant organ risk changes.",
      "paragraphs": [
        "Repeat focused review for Raynaud progression, puffy hands or sclerodactyly, inflammatory arthritis, weakness, dysphagia, dyspnea, exercise desaturation, pleuritic symptoms, and cardiac symptoms at follow-up. The rationale is that MCTD manifestations may emerge sequentially, and serious pulmonary or cardiac complications can become evident after the initial rheumatologic presentation. [5][18][19]",
        "Prioritize repeat cardiopulmonary testing when lung disease, Raynaud phenomenon, or hypergammaglobulinemia are present in overlap autoimmune disease. In an anti-Ku systemic autoimmune cohort, baseline lung involvement, Raynaud phenomenon, and elevated gammaglobulins were associated with incident cardiac involvement; baseline lung involvement remained independently associated after multivariable adjustment (hazard ratio 2.87, 95% CI 1.23-6.70). [2]",
        "Maintain diagnostic flexibility when renal or central nervous system findings are prominent. Severe renal and severe central nervous system involvement are described as uncommon in MCTD, so a major nephritic, nephrotic, or CNS syndrome should prompt reassessment for an alternative or additional connective-tissue disease phenotype. [18]"
      ],
      "bullets": [
        "Trend DLCO and lung volumes rather than relying only on symptoms; worsening DLCO with preserved volumes is a pulmonary vascular warning pattern. [18]",
        "Repeat echocardiography when new dyspnea, declining exercise capacity, elevated BNP, worsening DLCO, or right-heart imaging abnormalities develop. [16][18]",
        "Reassess for erosive articular disease when persistent synovitis develops because erosions can occur in MCTD. [18]"
      ],
      "subsections": [],
      "table": null
    }
  ],
  "faq": [
    {
      "question": "When should anti-U1-RNP-positive patients undergo pulmonary hypertension screening?",
      "answer": "At significant clinical suspicion of MCTD, obtain PFTs and transthoracic echocardiography as part of baseline organ staging; HRCT and further pulmonary hypertension evaluation are indicated when symptoms, physiologic abnormalities, or imaging findings suggest ILD or pulmonary vascular disease. [16][18][19]"
    },
    {
      "question": "Does anti-U1-RNP positivity establish MCTD?",
      "answer": "No. Anti-U1-RNP is central to the diagnosis, but it also occurs in SLE, systemic sclerosis, and myositis. Diagnose MCTD only in the context of a compatible overlap phenotype and longitudinal clinical assessment. [20][22][24]"
    }
  ],
  "references": [
    {
      "number": 1,
      "title": "Cluster analysis identifies three clinical patterns of patients ...",
      "detail": "rmdopen.bmj.com",
      "url": "https://rmdopen.bmj.com/content/rmdopen/11/2/e005191.full.pdf",
      "authors": "rmdopen.bmj.com",
      "host": "rmdopen.bmj.com"
    },
    {
      "number": 2,
      "title": "Cluster analysis identifies three clinical patterns of patients with systemic autoimmune diseases and anti-Ku antibodies | RMD Open",
      "detail": "rmdopen.bmj.com",
      "url": "https://rmdopen.bmj.com/content/11/2/e005191",
      "authors": "rmdopen.bmj.com",
      "host": "rmdopen.bmj.com"
    },
    {
      "number": 3,
      "title": "Integrating the autoimmune connective tissue diseases for ...",
      "detail": "www.cell.com",
      "url": "https://www.cell.com/heliyon/fulltext/S2405-8440(23)04142-7",
      "authors": "www.cell.com",
      "host": "www.cell.com"
    },
    {
      "number": 4,
      "title": "Muscle Involvement in Mixed Connective Tissue Disease - ScienceDirect",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S0889857X05000165",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 5,
      "title": "Pulmonary Manifestations of Systemic Sclerosis and Mixed Connective Tissue Disease - ScienceDirect",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0272523119300292?via%3Dihub=",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 6,
      "title": "Multifactorial pulmonary hypertension in a patient with antisynthetase syndrome - ScienceDirect",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0002962925014132",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 7,
      "title": "Pulmonary Complications of Childhood Rheumatic Disease - ScienceDirect",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S1526054211000479",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 8,
      "title": "Support needs and non-pharmacological interventions for ...",
      "detail": "ero.eular.org",
      "url": "https://ero.eular.org/article/S3050-7081(25)00107-7/pdf",
      "authors": "ero.eular.org",
      "host": "ero.eular.org"
    },
    {
      "number": 9,
      "title": "ERS/EULAR clinical practice guidelines for connective tissue ...",
      "detail": "ard.eular.org",
      "url": "https://ard.eular.org/article/S0003-4967(25)04320-1/fulltext",
      "authors": "ard.eular.org",
      "host": "ard.eular.org"
    },
    {
      "number": 10,
      "title": "Gastrointestinal Manifestations of Mixed Connective Tissue ...",
      "detail": "www.gastrojournal.org",
      "url": "https://www.gastrojournal.org/article/S0016-5085(12)90338-8/pdf",
      "authors": "www.gastrojournal.org",
      "host": "www.gastrojournal.org"
    },
    {
      "number": 11,
      "title": "an international collaborative tool to facilitate myositis research",
      "detail": "ard.eular.org",
      "url": "https://ard.eular.org/article/S0003-4967(24)01025-2/fulltext",
      "authors": "ard.eular.org",
      "host": "ard.eular.org"
    },
    {
      "number": 12,
      "title": "POS1199 A NOVEL AGE-DEFINED PHENOTYPIC LANDSCAPE IN ...",
      "detail": "ard.eular.org",
      "url": "https://ard.eular.org/article/S0003-4967(25)02601-9/abstract",
      "authors": "ard.eular.org",
      "host": "ard.eular.org"
    },
    {
      "number": 13,
      "title": "Clinical relevance of HEp-2 indirect immunofluorescent patterns",
      "detail": "ard.eular.org",
      "url": "https://ard.eular.org/article/S0003-4967(24)02269-6/fulltext",
      "authors": "ard.eular.org",
      "host": "ard.eular.org"
    },
    {
      "number": 14,
      "title": "Interstitial lung disease awareness among patients with ...",
      "detail": "ero.eular.org",
      "url": "https://ero.eular.org/article/S3050-7081(26)00091-1/pdf",
      "authors": "ero.eular.org",
      "host": "ero.eular.org"
    },
    {
      "number": 15,
      "title": "Nephrotic syndrome complicating connective tissue disease",
      "detail": "www.kidney-international.org",
      "url": "https://www.kidney-international.org/article/S0085-2538(15)31996-7/fulltext",
      "authors": "www.kidney-international.org",
      "host": "www.kidney-international.org"
    },
    {
      "number": 16,
      "title": "The Role of Anti-U1 RNP Antibody in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9821587",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 17,
      "title": "Research advances in connective tissue disease-associated ...",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13180610",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 18,
      "title": "Connective tissue disease‐associated pulmonary hypertension: A comprehensive review",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10711418",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 19,
      "title": "Towards Early Diagnosis of Mixed Connective Tissue Disease: Updated Perspectives",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10387239",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 20,
      "title": "Comparative study of 4 diagnosis criteria sets for mixed ...",
      "detail": "pubmed.ncbi.nlm.nih.gov",
      "url": "https://pubmed.ncbi.nlm.nih.gov/8970041",
      "authors": "pubmed.ncbi.nlm.nih.gov",
      "host": "pubmed.ncbi.nlm.nih.gov"
    },
    {
      "number": 21,
      "title": "Mixed Connective Tissue Disease - StatPearls - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK542198",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov"
    },
    {
      "number": 22,
      "title": "Mixed connective tissue disease - PubMed",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/pubmed/27421219",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov"
    },
    {
      "number": 23,
      "title": "Update in diagnosis and management of interstitial lung disease  - PMC",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6297625",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov"
    },
    {
      "number": 24,
      "title": "C1 PAGE.indd",
      "detail": "www.neurology.org",
      "url": "https://www.neurology.org/cms/asset/1b6419b6-689f-4379-a197-08ec37a617ff/nxi.12.issue-4.pdf",
      "authors": "www.neurology.org",
      "host": "www.neurology.org"
    }
  ],
  "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.",
  "citations": [
    {
      "number": 1,
      "title": "Cluster analysis identifies three clinical patterns of patients ...",
      "detail": "rmdopen.bmj.com",
      "url": "https://rmdopen.bmj.com/content/rmdopen/11/2/e005191.full.pdf",
      "authors": "rmdopen.bmj.com",
      "host": "rmdopen.bmj.com",
      "snippet": "4 (9.3) 0.4† Organ involvements (at diagnosis) Skin/mucosal involvement, n (%) 153 109 (71) 33 (79) 41 (59) 35 (83) 0.012† \u0007 Raynaud’s phenomenon 150 64 (43) 26 (62) 23 (34) 15 (38) 0.011† \u0007 Dryness 141 47 (33) 13 (36) 27 (42) 7 (18) 0.037† \u0007 Lupus rash 150 29 (19) 1 (2.4) 2 (2.9) 26 (63) <0.001† \u0007 ",
      "score": 0.21236303
    },
    {
      "number": 2,
      "title": "Cluster analysis identifies three clinical patterns of patients with systemic autoimmune diseases and anti-Ku antibodies | RMD Open",
      "detail": "rmdopen.bmj.com",
      "url": "https://rmdopen.bmj.com/content/11/2/e005191",
      "authors": "rmdopen.bmj.com",
      "host": "rmdopen.bmj.com",
      "snippet": "involvement at diagnosis (N=123), we identified that baseline lung involvement, Raynaud's phenomenon and elevated gammaglobulins were associated with the risk of incident cardiac involvement during follow-up in univariable analyses (HR 3.20, 95% CI 1.51 to 6.78; HR 2.16, 95% CI 1.02 to 4.58; HR 2.52",
      "score": 0.1711723
    },
    {
      "number": 3,
      "title": "Integrating the autoimmune connective tissue diseases for ...",
      "detail": "www.cell.com",
      "url": "https://www.cell.com/heliyon/fulltext/S2405-8440(23)04142-7",
      "authors": "www.cell.com",
      "host": "www.cell.com",
      "snippet": "by ABL Resende · 2023 · Cited by 7 — In this study, we aimed to review the immune mechanisms of the main SCTDs and to propose a classification system focused on the student and based on each immune",
      "score": 0.0909696
    },
    {
      "number": 4,
      "title": "Muscle Involvement in Mixed Connective Tissue Disease - ScienceDirect",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S0889857X05000165",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "Title: Muscle Involvement in Mixed Connective Tissue Disease - ScienceDirect\n# Muscle Involvement in Mixed Connective Tissue Disease. Myositis tends to be a feature of MCTD in the earlier phases of the disease; it is the presenting symptom only rarely. ### Mixed connective tissue disease: an apparen",
      "score": 0.6599319
    },
    {
      "number": 5,
      "title": "Pulmonary Manifestations of Systemic Sclerosis and Mixed Connective Tissue Disease - ScienceDirect",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0272523119300292?via%3Dihub=",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "Title: Pulmonary Manifestations of Systemic Sclerosis and Mixed Connective Tissue Disease - ScienceDirect\n# Pulmonary Manifestations of Systemic Sclerosis and Mixed Connective Tissue Disease. Check access to the full text by signing in through your organization. Pulmonary complications of systemic s",
      "score": 0.61834323
    },
    {
      "number": 6,
      "title": "Multifactorial pulmonary hypertension in a patient with antisynthetase syndrome - ScienceDirect",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0002962925014132",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "Title: Multifactorial pulmonary hypertension in a patient with antisynthetase syndrome - ScienceDirect\n## The American Journal of the Medical Sciences. # #129 Multifactorial pulmonary hypertension in a patient with antisynthetase syndrome. ### Case Report. Introduction: Pulmonary hypertension (pHTN)",
      "score": 0.5806618
    },
    {
      "number": 7,
      "title": "Pulmonary Complications of Childhood Rheumatic Disease - ScienceDirect",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S1526054211000479",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "# Mini-Symposium: Pulmonary Complications Paediatric Systemic Disorders Pulmonary Complications of Childhood Rheumatic Disease. Pulmonary manifestation occurs in nearly all childhood rheumatic diseases, either secondary to the underlying disease, or as adverse effects of drug treatments. Pulmonary m",
      "score": 0.43929082
    },
    {
      "number": 8,
      "title": "Support needs and non-pharmacological interventions for ...",
      "detail": "ero.eular.org",
      "url": "https://ero.eular.org/article/S3050-7081(25)00107-7/pdf",
      "authors": "ero.eular.org",
      "host": "ero.eular.org",
      "snippet": "by CMT Madsen · 2025 — Mixed connective tissue disease: state of the art on clinical practice guidelines. RMD · Open 2018;4(suppl 1):e000783. [9] Stöcker JK, Schouffoer AA",
      "score": 0.64880073
    },
    {
      "number": 9,
      "title": "ERS/EULAR clinical practice guidelines for connective tissue ...",
      "detail": "ard.eular.org",
      "url": "https://ard.eular.org/article/S0003-4967(25)04320-1/fulltext",
      "authors": "ard.eular.org",
      "host": "ard.eular.org",
      "snippet": "by KM Antoniou · 2026 · Cited by 189 — We suggest treating patients with any CTD-ILD with a combination of immunosuppressants or, in the presence of progressive pulmonary fibrosis,",
      "score": 0.45769477
    },
    {
      "number": 10,
      "title": "Gastrointestinal Manifestations of Mixed Connective Tissue ...",
      "detail": "www.gastrojournal.org",
      "url": "https://www.gastrojournal.org/article/S0016-5085(12)90338-8/pdf",
      "authors": "www.gastrojournal.org",
      "host": "www.gastrojournal.org",
      "snippet": "by JB Marshall · 1990 · Cited by 145 — Mixed connective tissue disease (MCTD) is a syndrome characterized by overlapping features of PSS, systemic lupus erythema- tosus (SLE), and polymyositis (PM),",
      "score": 0.43856934
    },
    {
      "number": 11,
      "title": "an international collaborative tool to facilitate myositis research",
      "detail": "ard.eular.org",
      "url": "https://ard.eular.org/article/S0003-4967(24)01025-2/fulltext",
      "authors": "ard.eular.org",
      "host": "ard.eular.org",
      "snippet": "by JB Lilleker · 2018 · Cited by 369 — Connective tissue disease-overlap myositis … is defined as the date of onset of the first symptoms of idiopathic inflammatory myopathy. Mixed connective tissue",
      "score": 0.392221
    },
    {
      "number": 12,
      "title": "POS1199 A NOVEL AGE-DEFINED PHENOTYPIC LANDSCAPE IN ...",
      "detail": "ard.eular.org",
      "url": "https://ard.eular.org/article/S0003-4967(25)02601-9/abstract",
      "authors": "ard.eular.org",
      "host": "ard.eular.org",
      "snippet": "Mixed connective tissue disease (MCTD) is a rare systemic autoimmune condition, primarily affecting women, with a prevalence of 4–10 cases per 100,000.",
      "score": 0.34959987
    },
    {
      "number": 13,
      "title": "Clinical relevance of HEp-2 indirect immunofluorescent patterns",
      "detail": "ard.eular.org",
      "url": "https://ard.eular.org/article/S0003-4967(24)02269-6/fulltext",
      "authors": "ard.eular.org",
      "host": "ard.eular.org",
      "snippet": "by J Damoiseaux · 2019 · Cited by 479 — Mixed connective tissue disease–an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA)",
      "score": 0.3421763
    },
    {
      "number": 14,
      "title": "Interstitial lung disease awareness among patients with ...",
      "detail": "ero.eular.org",
      "url": "https://ero.eular.org/article/S3050-7081(26)00091-1/pdf",
      "authors": "ero.eular.org",
      "host": "ero.eular.org",
      "snippet": "by O Distler · Cited by 1 — Connective tissue diseases (CTDs) and rheumatoid arthritis. (RA) are heterogeneous multiorgan autoimmune diseases with a common feature of lung involvement that",
      "score": 0.1426019
    },
    {
      "number": 15,
      "title": "Nephrotic syndrome complicating connective tissue disease",
      "detail": "www.kidney-international.org",
      "url": "https://www.kidney-international.org/article/S0085-2538(15)31996-7/fulltext",
      "authors": "www.kidney-international.org",
      "host": "www.kidney-international.org",
      "snippet": "by RJ Glassock · 1978 · Cited by 3 — Treatment with aspirin, aeetaminophen, and indomethaein produced some relief, but more definite improvement followed the administration of parenteral gold",
      "score": 0.061723232
    },
    {
      "number": 16,
      "title": "The Role of Anti-U1 RNP Antibody in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9821587",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "##  is a progressive disease characterized by increased pulmonary arterial pressure and pulmonary vascular resistance resulting from loss and obstructive remodeling of the pulmonary vascular bed. According to the latest 2022 guideline of the European Society of Cardiology and the European Respirator",
      "score": 0.7060491
    },
    {
      "number": 17,
      "title": "Research advances in connective tissue disease-associated ...",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13180610",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "MCTD-PAH within the anti-U1-RNP antibody-positive population. Diagnostic value of transthoracic doppler echocardiography in pulmonary hypertension:",
      "score": 0.6490677
    },
    {
      "number": 18,
      "title": "Connective tissue disease‐associated pulmonary hypertension: A comprehensive review",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10711418",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "MCTD is a systemic autoimmune rheumatic disease characterized by a positive U1‐RNP antibody, some combination of Raynaud phenomenon, puffy hands, sclerodactyly, synovitis, and myositis, and overlapping features of SLE, SSc, RA, and idiopathic inflammatory myopathy.59 Given the variable presentation ",
      "score": 0.6453216
    },
    {
      "number": 19,
      "title": "Towards Early Diagnosis of Mixed Connective Tissue Disease: Updated Perspectives",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10387239",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "An early diagnosis of MCTD generally starts with the recognition of RA-like inflammatory arthritis, RP, myalgia/myositis, and rarely, trigeminal neuropathy. These signs can be present alone or in combination. A correct early diagnosis can be made starting with the presence of the anti-U1RNP antibody",
      "score": 0.5488434
    },
    {
      "number": 20,
      "title": "Comparative study of 4 diagnosis criteria sets for mixed ...",
      "detail": "pubmed.ncbi.nlm.nih.gov",
      "url": "https://pubmed.ncbi.nlm.nih.gov/8970041",
      "authors": "pubmed.ncbi.nlm.nih.gov",
      "host": "pubmed.ncbi.nlm.nih.gov",
      "snippet": "by JM Amigues · 1996 · Cited by 216 — As anti-U1-RNP antibodies appear indispensable to establish the diagnosis of MCTD, We tested criteria for rheumatoid arthritis, The criteria that best",
      "score": 0.4547875
    },
    {
      "number": 21,
      "title": "Mixed Connective Tissue Disease - StatPearls - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK542198",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov",
      "snippet": "Mixed connective tissue disease (MCTD) is a rare systemic autoimmune disease with the main features of at least 2 overlapping connective tissue diseases, including systemic lupus erythematosus, systemic sclerosis, polymyositis, dermatomyositis, and rheumatoid arthritis. The disease is also defined b",
      "score": 0.42907107
    },
    {
      "number": 22,
      "title": "Mixed connective tissue disease - PubMed",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/pubmed/27421219",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov",
      "snippet": "An official website of the United States government. The ** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. ## Save citation to file. ## Email citation. Go to My NCBI account settings to confirm your email and then r",
      "score": 0.6821721
    },
    {
      "number": 23,
      "title": "Update in diagnosis and management of interstitial lung disease  - PMC",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6297625",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov",
      "snippet": "Title: Update in diagnosis and management of interstitial lung disease  - PMC\n**KEYWORDS:** Cryoscopic lung biopsy, idiopathic pulmonary fibrosis, interstitial lung disease. NSIP = non-specific interstitial pneumonitis. IPF does not respond to immunosuppressive therapy; in fact, immunomodulation may",
      "score": 0.44985238
    },
    {
      "number": 24,
      "title": "C1 PAGE.indd",
      "detail": "www.neurology.org",
      "url": "https://www.neurology.org/cms/asset/1b6419b6-689f-4379-a197-08ec37a617ff/nxi.12.issue-4.pdf",
      "authors": "www.neurology.org",
      "host": "www.neurology.org",
      "snippet": "I, Corse AM, et al. Muscular and extramuscular features of myositis patients with anti-U1-RNP autoantibodies. Neurology . 2019; 92(13):e1416-e1426. doi:10.1212/WNL.0000000000007188 35. Okawa-Takatsuji M, Aotsuka S, Uwatoko S, et al. Endothelial cell-binding activity of anti-U1-ribonucleoprotein anti",
      "score": 0.6347929
    }
  ],
  "publishedAt": "2026-08-24T18:23:37.058205+00:00",
  "updatedAt": "2026-08-24T18:23:37.058205+00:00",
  "readingMinutes": 6,
  "slug": "mixed-connective-tissue-disease"
}